CEBU, Philippines -- Malaysia's IHH Healthcare has led a $20-million Series A funding round for Singapore-based Lucence, the inventor of blood-based tests for cancer screening and treatment selection, the companies announced Wednesday.
The financing, which will be used by Lucence to bring its liquid biopsy technology to more patients across Asia and North America, was joined by SGInnovate, Temasek's subsidiary Heliconia Capital, Lim Kaling, Koh Boon Hwee, and others.
